MedPage Today on MSN
Prior Ibrutinib May Improve CAR-T Efficacy in Rare Lymphoma
Findings could be practice changing if proven prospectively, experts say ...
Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR ...
What Is Breyanzi, and Why Does It Matter? Breyanzi (lisocabtagene maraleucel) is a type of personalized cancer treatment called chimeric antigen receptor (CAR) T-cell therapy, which uses your modified ...
Side effects of Lymphir are generally mild to moderate and manageable, with rapid relief from severe itching often observed. Lymphir's availability offers disease control and quality of life ...
News Medical on MSN
FDA label update expands CAR T access for primary CNS lymphoma
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results